NCT00997386
- Conditions
- Anemia, Anemia, Aplastic, Anemia, Hemolytic, +27 more
- Locations
-
- University Medical Center and UMC-North Clinic Tucson, Arizona, United States
Clinical trial condition
Paraproteinemias
Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.
3,006 public trials
571 recruiting studies
Paraproteinemias trial results
NCT01818752
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
- Locations
-
- California Cancer Associates for Research & Excellence, Inc. (cCARE) Fresno, California, United States
- Marin Cancer Care Greenbrae, California, United States
- Sutter Gould Medical Foundation Modesto, California, United States
- Innovative Clinical Research Institute Whittier, California, United States
NCT00474929
- Conditions
- Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +44 more
- Locations
-
- Holden Comprehensive Cancer Center at University of Iowa Iowa City, Iowa, United States
- Mayo Clinic Cancer Center Rochester, Minnesota, United States
Completed
Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma
NCT02976493
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
- Locations
-
- Local Institution Shinjuku-ku, Tokyo, Japan
Completed
Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
NCT00937183
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
- Locations
-
- Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology - Warsaw Warsaw, Poland
Completed
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
NCT00932698
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
- Locations
-
- H. Lee Moffitt Cancer Center Tampa, Florida, United States
- Emory University Atlanta, Georgia, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
- University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
Completed
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01839916
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), +134 more
- Locations
-
- University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
NCT01001442
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
- Locations
-
- Emory University Winship Cancer Institute Atlanta, Georgia, United States
- The University of Chicago Chicago, Illinois, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
- Roswell Park Cancer Institute Buffalo, New York, United States
Completed
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02950220
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Blood Protein Disorders, Burkitt Lymphoma, +46 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
NCT02880228
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
- Locations
-
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Mayo Clinic Rochester, Minnesota, United States